LIXTE Biotechnology Steps into Next-Gen Cancer Treatment with Liora Acquisition
LIXTE Biotechnology bought Liora Technologies to get the LiGHT System, a cutting-edge, high-precision proton therapy for cancer treatment.
/ 1665 items
#XY↓
UK NICE Approves AUCATZYL CAR T Therapy for Adult B-ALL Patients
NICE recommends Autolus AUCATZYL (obecabtagene autoleucel) for adults 26+ with relapsed/refractory B-cell acute lymphoblastic leukemia in England and Wales.
Inspire Medical Soars 29% on Medicare Payment Boost
Inspire Medical Systems stock jumps after CMS approves major Medicare payment increase for sleep apnea procedures, effective 2026. Stifel upgrades to Buy.
Arcellx Stock Dips on Kelonia's Early CAR-T Data: Analyst Calls Reaction "Overdone"
Guggenheim analyst says Arcellx stock decline is overdone after competitor Kelonia released early Phase 1 CAR-T therapy data. Maintains Buy rating despite market pressure.
Evercore ISI Begins Coverage of Beam Therapeutics With Bullish Outlook
Evercore ISI initiates coverage of Beam Therapeutics (BEAM) with an Outperform rating and $35 price target, citing promising early data for BEAM-302 in treating AATD and highlighting key data expected in Q1 2026.
Bayer's Stroke Prevention Drug Shows Promise, Reviving Hope for New Blood Clot Treatment Class
Bayer's asundexian succeeds in Phase 3 stroke prevention trial, becoming first FXIa inhibitor to show positive results and potentially opening door for safer blood clot medications.